Molecure S.A.

Warsaw Stock Exchange MOC.WA

Molecure S.A. Capital Expenditure for the year ending December 31, 2023: USD -11.29 M

Molecure S.A. Capital Expenditure is USD -11.29 M for the year ending December 31, 2023, a -47.08% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Molecure S.A. Capital Expenditure for the year ending December 31, 2022 was USD -7.68 M, a -64.75% change year over year.
Molecure S.A. Capital Expenditure for the year ending December 31, 2021 was USD -4.66 M, a -734.21% change year over year.
Molecure S.A. Capital Expenditure for the year ending December 31, 2020 was USD -558.53 K, a 93.92% change year over year.
Molecure S.A. Capital Expenditure for the year ending December 31, 2019 was USD -9.18 M, a -25.56% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Warsaw Stock Exchange: MOC.WA

Molecure S.A.

CEO	Dr. Marcin Jan Szumowski Ph.D.
IPO Date	April 1, 2018
Location	Poland
Headquarters	Zwirki i Wigury 101
Employees	105
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.

Key trends

Past 5 years